University Of Edinburgh
- Address
- 47 Little France Crescent, Bioquarter
Sponsor Overview
Specializations
Bone Fragility Disorders
Research activity includes osteogenesis imperfecta, with interest in therapies aimed at reducing fracture risk and supporting skeletal strength. The focus extends to treatment strategies involving parathyroid hormone analogues and bisphosphonates, as well as sequential approaches to bone protection.
- Osteogenesis imperfecta
- Fracture prevention
- Bone metabolism
- Bisphosphonate therapy
These interests reflect a clinical emphasis on inherited skeletal disease and interventions that target bone density and structural resilience.
Stroke and Cerebrovascular Injury
The sponsor also funds research in survivors of intracerebral haemorrhage, with attention to recovery after stroke and prevention of later cerebrovascular events. This area includes evaluation of antiplatelet therapy in the context of post-hemorrhagic brain injury.
- Intracerebral haemorrhage
- Stroke survivorship
- Antiplatelet therapy
- Major adverse cardiovascular or cerebrovascular events
Clinical interest is centered on balancing vascular protection with neurological safety in patients recovering from hemorrhagic stroke.
Cardiovascular and Cerebrovascular Risk Reduction
Trial activity includes outcomes related to major adverse cardiovascular or cerebrovascular events, highlighting interest in secondary prevention after brain hemorrhage. The research landscape spans both cardiovascular and cerebrovascular risk management in vulnerable patient groups.
- Secondary prevention
- Cerebrovascular risk
- Cardiovascular risk
- Post-stroke management
This field connects acute neurological disease with longer-term prevention of recurrent vascular complications.
Musculoskeletal Therapeutics
Work in this area supports investigation of treatments that influence bone remodelling and skeletal integrity. The sponsor’s portfolio includes interest in agents used for strengthening bone tissue and reducing the burden of recurrent injury in chronic bone disease.
- Bone remodelling
- Skeletal integrity
- Bone-strengthening therapy
- Chronic bone disease
These topics place emphasis on long-term management of disorders where bone fragility is a central clinical concern.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Acetylsalicylic Acid and Clopidogrel Monotherapy for Secondary Prevention in Intracerebral Hemorrhage Survivors: A Randomized Controlled Trial |  Belgium The Netherlands | Recruiting |
| Evaluation of Teriparatide and Zoledronic Acid in the Management of Osteogenesis Imperfecta: A Randomized Controlled Trial |  Denmark France Ireland The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 13 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 29 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases1 trial359 other sponsors
- 2.Musculoskeletal and Neural Physiological Phenomena1 trial28 other sponsors
- 3.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
29 centres- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- Molengracht 21, 4818 CK Breda
- Address
- De Boelelaan 1117, 1081 HV Amsterdam
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Campus Kennedylaan, President Kennedylaan 4, 8500 Kortrijk
- Address
- Michelangelolaan 2, 5623 EJ Eindhoven
Want to get in touch with this sponsor?
Send a question and we'll pass it on to University Of Edinburgh.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.